Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;62(5):435-40.
doi: 10.4097/kjae.2012.62.5.435. Epub 2012 May 24.

Efficacy and safety of a lidocaine/tetracaine medicated patch or peel for dermatologic procedures: a meta-analysis

Affiliations

Efficacy and safety of a lidocaine/tetracaine medicated patch or peel for dermatologic procedures: a meta-analysis

Won Oak Kim et al. Korean J Anesthesiol. 2012 May.

Abstract

Background: To justify the use of the lidocaine/tetracaine medicated patch or peel as a preventive treatment for reducing pain and discomfort in adults and children. We reviewed randomized controlled trials (RCTs) to evaluate the efficacy and safety of the lidocaine/tetracaine medicated patch or peel compared with placebo.

Methods: Ten RCTs (574 patients) were included in this systemic review. Relevant studies were identified through searches of MEDLINE, SCOPUS and the Cochrane database library. The outcome was the adequacy of cutaneous anesthesia reflected in the patient's assessment of pain intensity during minor dermatologic procedures and adverse effects after application of the lidocaine/tetracaine medicated patch or peel versus placebo.

Results: The efficacy of the lidocaine/tetracaine patch or peel was consistently very significantly beneficial 30 or 60 minutes after the application compared to placebo (Relative risk, RR: 2.5; Number needed to treat, NNT: 2.2). We did not identify any difference in the effectiveness of adequate analgesia between the lidocaine/tetracaine patch and peel (the number needed to treat or to harm, NNT 2.4 vs. 2.0). No serious side effects or adverse events were observed with the lidocaine/tetracaine medicated patch or peel and placebo. Minor skin reactions were transient and resolved without treatment (Odd ratio, OR: 1.4 and 95% confidence interval, CI: 0.9-2.1; NNT: 14.9).

Conclusions: The lidocaine/tetracaine medicated patch or peel is a well accepted, effective and safe method for minor dermatologic procedures based on pooled data of trials in terms of adequacy of cutaneous anesthesia and adverse effects.

Keywords: Lidocaine; Meta-analysis; Tetracaine; Topical anesthetics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
An annotated forest plot (adequacy of cutaneous anesthesia) shows individual trials, depicted as filled squares, with the relative size of weights and horizontal bars as the confidence interval. The bottom diamond shape refers to the pooled value. RR: relative risk.
Fig. 2
Fig. 2
An annotated forest plot (adverse effects) shows individual trials, depicted as filled squares, with the relative size of weights and horizontal bars as the confidence interval. The bottom diamond shape refers to the pooled value. OR: odd ratio.

References

    1. Eidelman A, Weiss JM, Lau J, Carr DB. Topical anesthetics for dermal instrumentation: a systematic review of randomized, controlled trials. Ann Emerg Med. 2005;46:343–351. - PubMed
    1. Chen BK, Cunningham BB. Topical anesthetics in children: agents and techniques that equally comfort patients, parents, and clinicians. Curr Opin Pediatr. 2001;13:324–330. - PubMed
    1. Croxtall JD. Lidocaine/tetracaine medicated plaster: in minor dermatological and needle puncture procedures. Drugs. 2010;70:2113–2120. - PubMed
    1. Shainhouse T, Cunningham BB. Topical anesthetics: physiology, formulations, and novel delivery systems. Am J Drug Deliv. 2004;2:89–99.
    1. Tadicherla S, Berman B. Percutaneous dermal drug delivery for local pain control. Ther Clin Risk Manag. 2006;2:99–113. - PMC - PubMed

LinkOut - more resources